Herpes Simplex Follow-up

  • Author: Michelle R Salvaggio, MD, FACP; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Jan 5, 2012
 

Deterrence/Prevention

Because of the ubiquitous and cosmopolitan nature of herpes simplex virus (HSV), avoiding contact with individuals who (often asymptomatically) are excreting the virus in saliva or genital secretions is difficult. Daily antiviral therapy can be given to reduce episodes of asymptomatic genital shedding and to further reduce the risk of transmission; however, it is unclear how long this should be administered.

Although not easily applicable to oral-oral contact, barrier protection using latex condoms is recommended to minimize exposure to genital HSV infections.

Because HSV genital ulcers may occur outside of areas covered by the condom, transmission can occur in those areas.

Herpetic whitlow can be avoided with latex gloves when health care workers insert their hands into the oral cavity of patients. Transmission of genital virus to the hand can occur during unprotected finger-genital contact during sexual activities.

Suppressive antiviral therapy can be used in individuals with frequent and/or particularly symptomatic relapses, but clinical trials have shown variable results.

Despite therapy with high-dose antivirals, HSV transmission may occur during suppressive antiviral therapy. In 3 separate but complementary crossover trials, Johnston et al studied the effect of various drug regimens on viral shedding in individuals who were HSV-2 seropositive. Treatment with either acyclovir 400 mg BID (standard-dose acyclovir) or valacyclovir 500 mg BID (standard-dose valacyclovir) with acyclovir 800 mg TID (high-dose acyclovir) was compared to no medication. Standard-dose valacyclovir was also compared with valacyclovir 1 g TID (high-dose valacyclovir). Results showed short bursts of subclinical genital HSV reactivation were frequent, even during high-dose antiherpes therapy.[31]

An investigational HSV vaccine was not effective in preventing HSV-2 disease or infection in a study population that was representative of the general population of HSV-1– and HSV-2–seronegative women. The investigational vaccine was effective in preventing HSV-1 genital disease and infection.[32]

Next

Complications

  • Bacterial and fungal superinfections are not uncommon.
    • Balanitis can occur in an uncircumcised male as a result of bacterial infection of the herpetic ulcers.
    • Candidal vaginitis has been described in as many as 10% of women with primary genital herpes, particularly in women with diabetes. Care should be taken to confirm the diagnosis of candidiasis, as ulcerative herpetic disease can have whitish mucosal lesions that can be confused with yeast infection.
  • Ocular infections
    • This complication is not uncommon in children as a result of autoinoculation during acute herpetic gingivostomatosis or asymptomatic oropharyngeal HSV infection.
    • Ocular infection is caused primarily by HSV-1, except in neonates, in whom it may be caused by HSV-2, and manifests as unilateral follicular conjunctivitis or as acute herpetic keratoconjuctivitis with dendritic corneal ulcers.[13]
    • Recurrences occur in as many as 25% of patients and can be associated with progressive scarring of the cornea. HSV has been the leading infectious cause of blindness in the United States.
  • Skin infections: Various cutaneous complications related to HSV can occur.
    • Eczema herpeticum: This occurs in individuals with underlying dermatitis and may be localized (which can be confused with herpes zoster) or disseminated. The process can also occur in patients with extensive skin breakdown as with burns, pemphigus, or Sézary syndrome.
    • Herpetic whitlow: HSV infections of the fingers occur at or near the cuticle or at other sites associated with trauma. When involving the nail area, it has been confused with a bacterial felon and been subjected, inappropriately, to incision and drainage. Herpetic whitlow is associated with HSV-1 in health care workers and children related to saliva exposure and with HSV-2 related to digital-genital exposure.
    • Herpes gladiatorum: Scattered cutaneous HSV-1 lesions have been observed in wrestlers who have had viral contact through exposure to infectious saliva during a match.
  • Visceral infections: HSV infection of the visceral organs usually results from viremia, and multiple organ involvement is common. This may occur during otherwise asymptomatic primary infections and sometimes in seemingly immunocompetent hosts.
    • In most cases of disseminated herpes, the lesions are confined to the skin; however, fatal visceral dissemination can occur with or without vesicular skin lesions. Multiple organs are involved, but fulminant HSV hepatitis is usually clinically prominent.
    • It is associated with leukopenia, thrombocytopenia, and disseminated intravascular coagulation.
    • Disseminated HSV-1 and HSV-2 infections can also result in herpetic esophagitis, adrenal necrosis, interstitial HSV pneumonitis, HSV cystitis, HSV arthritis, HSV meningitis, and HSV encephalitis.
  • Central nervous system complications[10, 14]
    • Aseptic meningitis: This condition is an acute, generally benign lymphocytic meningitis. In one series, 36% of women and 13% of men with primary genital HSV-2 infection had meningeal symptoms on two consecutive examinations. It is more common with HSV-2 infection. Meningeal symptoms usually start 3-12 days after the onset of genital lesions; they reach a maximum 2-4 days into the illness and recede over 2-4 days. Signs and symptoms of encephalitis are unusual, and neurological sequelae are rare. HSV-1 also has been identified by PCR in the CSF of patients with benign lymphocytic recurrent meningitis (Mollaret meningitis), suggesting that HSV may be the cause of this so-called idiopathic syndrome.
    • Ganglionitis and myelitis: Genital and anorectal HSV infections may be complicated by urinary retention, sacral neuralgia, and sacral anesthesia. This is due to associated ganglionitis and radiculitis. The symptoms usually resolve in 1-2 weeks. Transverse myelitis is rarely reported.
    • Herpes simplex encephalitis: This is an acute necrotizing viral encephalitis that, beyond the neonatal period, is nearly always caused by HSV-1. It accounts for 10%-20% of all cases of encephalitis and is the most common cause of sporadic acute necrotizing encephalitis in the United States. Herpes simplex encephalitis occurs as a primary infection in about 50% of cases and may be due to recurrent infection or to reinfection with a different strain of HSV-1 in the remainder. Clinical features include the following:
      • Nonspecific findings common to all forms of encephalitis, which include headache, signs of meningeal irritation, altered mental status, and generalized seizures
      • Changes referable to focal necrosis of the orbitofrontal and temporal cortex and the limbic system, including anosmia, memory loss, olfactory and gustatory hallucinations, and focal seizures
      • Rapid development of hemiparesis and coma may occur. In some patients, the clinical picture is protracted, mimicking acute psychosis or delirium tremens.
      • The CSF has moderate pleocytosis with mixed mononuclear cells and polymorphonuclear cells, moderate RBC counts, and mildly elevated protein levels with normal glucose levels.
      • MRI is the most sensitive imaging procedure.
      • The most sensitive noninvasive method of diagnosis is the demonstration of HSV DNA by PCR.
      • The mortality rate is high (70%) in untreated patients. Even with treatment, a high incidence of neurological sequelae remains.
  • Genital herpes and pregnancy
    • Recurrent genital herpes is similar in pregnant and nonpregnant women, although an increase in the number of recurrences in the course of pregnancy may occur.
    • Recurrent genital herpes accounts for 1%-2% of all cases of neonatal herpes. Cesarean delivery is recommended in mothers who have active genital lesions during labor. However, presence of active genital lesions is not a good indicator of HSV viral shedding.[15] Thus the American College of Obstetricians and Gynecologists (ACOG) recommends that suppressive antiviral therapy be given to all women with a history of recurrent genital HSV in the last 4 weeks of pregnancy.[16]
    • A large nationwide cohort study in Denmark did not find any association between first trimester in utero antiviral drug (ie, acyclovir, valacyclovir, famciclovir) exposure and birth congenital anomalies. In 1804 pregnancies exposed to an antiviral drug during the first trimester, 40 infants (2.2%) were diagnosed with a major birth defect compared with 19,920 (2.4%) unexposed pregnancies.[17]
    • Primary genital infection during pregnancy
      • First-episode infections have more severe consequences to the mother and infant. Thus, identification of women at risk for primary infection (seronegative for HSV-2) is paramount.
      • Serological discordance between partners may be 15%-20%, so that the risk of a seronegative mother becoming infected from the father during pregnancy is 10%-15%.
      • Pregnant women may have widely disseminated infection with a high mortality rate (50%).
      • Infection in the third trimester of pregnancy is associated with neonatal HSV infections, intrauterine growth retardation, and prematurity.
  • Neonatal HSV disease
    • Ninety percent of infections are acquired perinatally, 5%-8% are acquired congenitally, and a few are acquired postnatally.
    • Neonatal HSV infection is caused by contact with infected genital secretions.
    • In 70% of mothers, the infection is asymptomatic. The risk of transmission from a mother with primary infection is about 50%.[18]
    • Neonates and infants (aged < 6 wk) have a very high frequency of visceral and CNS infections. Without therapy, the mortality rate is 65%, and a high degree of neurological sequelae exists.
    • The disease may be confined to the skin, eyes, or mouth, or it may manifest as encephalitis or disseminated visceral disease involving the lungs, liver, heart, adrenals, and skin. This neonate displayed a maculopapular outbreak onThis neonate displayed a maculopapular outbreak on his feet due to congenitally acquired herpes simplex virus infection. Courtesy of the CDC/Judith Faulk.
  • Copathogenesis with HIV: Multiple studies have shown that the presence of antibodies to HSV-2 increases the risk of becoming infected with HIV, independent of the presence of genital ulcers.[19] While early studies in Africa have demonstrated a reduction of HIV viral load in patients with HIV infection receiving therapy directed toward HSV infection, the mechanism is unclear.[20, 21] The association between HIV and HSV may change the epidemiologic approach to sexually transmitted diseases worldwide.
Previous
Next

Patient Education

For excellent patient education resources, visit eMedicine's Sexually Transmitted Diseases Center and Teeth and Mouth Center. Also, see eMedicine's patient education articles Genital Herpes, Oral Herpes, Birth Control Overview, and Birth Control FAQs.

Previous
 
Contributor Information and Disclosures
Author

Michelle R Salvaggio, MD, FACP  Assistant Professor, Department of Internal Medicine, Section of Infectious Diseases, University of Oklahoma College of Medicine; Medical Director of Infectious Diseases Institute, Director, Clinical Trials Unit, Director, Ryan White Programs, Department of Medicine, University of Oklahoma Health Sciences Center; Attending Physician, Infectious Diseases Consultation Service, Infectious Diseases Institute, OU Medical Center

Michelle R Salvaggio, MD, FACP is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Merck Honoraria Speaking and teaching

Coauthor(s)

Larry I Lutwick, MD  Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Meena Seenivasan, MD  Fellow, Department of Infectious Disease, State University of New York Health Science Center at Brooklyn

Disclosure: Nothing to disclose.

Swati Kumar, MD  Assistant Professor of Pediatrics, Division of Infectious Diseases, Medical College of Wisconsin, Consulting Staff, Children's Specialty Group, Children's Hospital of Wisconsin

Swati Kumar, MD is a member of the following medical societies: American Academy of Pediatrics, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas J Marrie, MD  Dean of Faculty of Medicine, Dalhousie University Faculty of Medicine, Canada

Thomas J Marrie, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society for Microbiology, Canadian Infectious Disease Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Charles V Sanders, MD  Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center

Charles V Sanders, MD is a member of the following medical societies: Alliance for the Prudent Use of Antibiotics, Alpha Omega Alpha, American Association for the Advancement of Science, American Association of University Professors, American Clinical and Climatological Association, American College of Physician Executives, American College of Physicians, American Federation for Medical Research, American Foundation for AIDS Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association for Professionals in Infection Control and Epidemiology, Association of American Medical Colleges, Association of American Physicians, Association of Professors of Medicine, Infectious Disease Society for Obstetrics and Gynecology, Infectious Diseases Society of America, Louisiana State Medical Society, Orleans Parish Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southeastern Clinical Club, Southern Medical Association, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References
  1. Corey L. Herpes Simplex Virus. In: Mandell Gl, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Pennsylvania: Elsevier; 2005:1762-80.

  2. Kimberlin DW, Rouse DJ. Clinical practice. Genital herpes. N Engl J Med. May 6 2004;350(19):1970-7. [Medline].

  3. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. Oct 15 2008;198(8):1141-9. [Medline].

  4. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. Oct 16 1997;337(16):1105-11. [Medline].

  5. Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral Dis. May 2006;12(3):254-70. [Medline].

  6. Spruance SL, Overall JC Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med. Jul 14 1977;297(2):69-75. [Medline].

  7. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. Jun 1983;98(6):958-72. [Medline].

  8. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. Sep 21 1995;333(12):770-5. [Medline].

  9. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med. Jul 6 1999;131(1):14-20. [Medline].

  10. Sköldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 and acute aseptic meningitis. Clinical features of cases with isolation of herpes simplex virus from cerebrospinal fluids. Scand J Infect Dis. 1975;7(4):227-32. [Medline].

  11. Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet. Jan 26 1991;337(8735):189-92. [Medline].

  12. Gnann JW, Salvaggio MR. Drugs for Herpesvirus Infections. In: Cohen J, Powderly W, eds. Infectious Diseases. Vol 2. 2nd ed. New York: Mosby; 2004:1895-909.

  13. Green LK, Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin. Spring 2006;46(2):27-37. [Medline].

  14. Whitley RJ. Herpes simplex virus infections of the central nervous system. A review. Am J Med. Aug 29 1988;85(2A):61-7. [Medline].

  15. Gardella C, Brown ZA, Wald A, Morrow RA, Selke S, Krantz E. Poor correlation between genital lesions and detection of herpes simplex virus in women in labor. Obstet Gynecol. Aug 2005;106(2):268-74. [Medline].

  16. American College Obstetricians and Gynecologists. Management of herpes in pregnancy. ACOG Practice Bulletin. October 1999;Number 8:644-652.

  17. [Best Evidence] Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. Aug 25 2010;304(8):859-66. [Medline].

  18. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. Jan 8 2003;289(2):203-9. [Medline].

  19. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. Apr 15 2004;35(5):435-45. [Medline].

  20. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. Feb 22 2007;356(8):790-9. [Medline].

  21. [Best Evidence] Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. Dec 15 2008;198(12):1804-8. [Medline].

  22. [Best Evidence] Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol. Mar 2006;194(3):774-81. [Medline].

  23. [Best Evidence] Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol. Jul 2006;108(1):141-7. [Medline].

  24. Hasegawa T, Kawana T, Okuda T, Horii M, Tsukada T, Shiraki K. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan. J Med Virol. Jan 2001;63(1):57-63. [Medline].

  25. Rabella N, Otegui M, Labeaga R, et al. Antiviral susceptibility of Herpes simplex viruses and its clinical correlates: a single center's experience. Clin Infect Dis. Apr 15 2002;34(8):1055-60. [Medline].

  26. Cunha BA, Eisenstein LE, Dillard T, Krol V. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Heart Lung. Jan-Feb 2007;36(1):72-8. [Medline].

  27. Cunha BA, Fatehpuria R, Eisenstein LE. Listeria monocytogenes encephalitis mimicking Herpes Simplex virus encephalitis: the differential diagnostic importance of cerebrospinal fluid lactic acid levels. Heart Lung. May-Jun 2007;36(3):226-31. [Medline].

  28. Eisenstein LE, Calio AJ, Cunha BA. Herpes simplex (HSV-1) aseptic meningitis. Heart Lung. May-Jun 2004;33(3):196-7. [Medline].

  29. Eisenstein LE, Cunha BA. Herpes simplex virus pneumonia presenting as failure to wean from a ventilator. Heart Lung. Jan-Feb 2003;32(1):65-6. [Medline].

  30. Mohan S, Hamid NS, Cunha BA. A cluster of nosocomial herpes simplex virus type 1 pneumonia in a medical intensive care unit. Infect Control Hosp Epidemiol. Nov 2006;27(11):1255-7. [Medline].

  31. Johnston C, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomized, open-label, cross-over trials [published online ahead of print January 5, 2012]. Lancet. doi:10.1016/S0140-6736(11)61750-9.

  32. Belshe RB, et al. Efficacy Results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34-43.

Previous
Next
 
This neonate displayed a maculopapular outbreak on his feet due to congenitally acquired herpes simplex virus infection. Courtesy of the CDC/Judith Faulk.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.